Chemed Corporation (NYSE:CHE) Announces $0.60 Quarterly Dividend

Chemed Corporation (NYSE:CHEGet Free Report) announced a quarterly dividend on Friday, February 13th. Investors of record on Monday, February 23rd will be given a dividend of 0.60 per share on Friday, March 13th. This represents a c) annualized dividend and a dividend yield of 0.5%. The ex-dividend date of this dividend is Monday, February 23rd.

Chemed has raised its dividend payment by an average of 0.1%per year over the last three years and has raised its dividend annually for the last 16 consecutive years. Chemed has a dividend payout ratio of 8.7% indicating that its dividend is sufficiently covered by earnings. Equities analysts expect Chemed to earn $23.30 per share next year, which means the company should continue to be able to cover its $2.40 annual dividend with an expected future payout ratio of 10.3%.

Chemed Price Performance

CHE traded up $3.24 during midday trading on Friday, reaching $475.35. 124,633 shares of the company’s stock were exchanged, compared to its average volume of 168,831. The business’s 50-day moving average price is $444.77 and its 200 day moving average price is $443.47. Chemed has a 1-year low of $408.42 and a 1-year high of $623.60. The stock has a market capitalization of $6.73 billion, a PE ratio of 25.14, a P/E/G ratio of 2.30 and a beta of 0.44.

Insider Buying and Selling

In related news, CEO Kevin J. Mcnamara sold 2,000 shares of the business’s stock in a transaction dated Monday, November 24th. The stock was sold at an average price of $437.55, for a total value of $875,100.00. Following the completion of the sale, the chief executive officer directly owned 94,197 shares of the company’s stock, valued at $41,215,897.35. The trade was a 2.08% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Company insiders own 3.29% of the company’s stock.

Institutional Investors Weigh In On Chemed

A number of institutional investors have recently made changes to their positions in the company. Commonwealth Equity Services LLC grew its holdings in shares of Chemed by 3.1% during the fourth quarter. Commonwealth Equity Services LLC now owns 734 shares of the company’s stock valued at $314,000 after purchasing an additional 22 shares during the last quarter. WCM Investment Management LLC grew its holdings in Chemed by 3.8% in the 3rd quarter. WCM Investment Management LLC now owns 661 shares of the company’s stock worth $299,000 after buying an additional 24 shares in the last quarter. Eukles Asset Management boosted its position in Chemed by 0.4% during the 3rd quarter. Eukles Asset Management now owns 6,031 shares of the company’s stock worth $2,700,000 after acquiring an additional 24 shares during the period. Cim LLC lifted its holdings in shares of Chemed by 1.1% in the third quarter. Cim LLC now owns 2,139 shares of the company’s stock valued at $958,000 after buying an additional 24 shares during the period. Finally, Atria Investments Inc raised its holdings in shares of Chemed by 0.6% in the 2nd quarter. Atria Investments Inc now owns 4,259 shares of the company’s stock worth $2,074,000 after purchasing an additional 25 shares in the last quarter. 95.85% of the stock is currently owned by institutional investors.

About Chemed

(Get Free Report)

Chemed Corporation is a diversified provider of essential home services and healthcare solutions in the United States. Headquartered in Cincinnati, Ohio, the company operates through two principal business segments—Roto-Rooter and Vitas Healthcare. Since its founding in 1974, Chemed has built a reputation for reliability and expertise, serving both residential and commercial customers across a broad range of markets.

The Roto-Rooter segment offers a comprehensive suite of plumbing, drain cleaning and water restoration services.

Further Reading

Dividend History for Chemed (NYSE:CHE)

Receive News & Ratings for Chemed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chemed and related companies with MarketBeat.com's FREE daily email newsletter.